Table II.
Laboratory findings on 80 frontline medical staff infected with COVID-19 on hospital admission
| Variables | All | SARS-CoV-2 confirmed (N = 57) | Clinically diagnosed (N = 23) | Reference |
P-value |
|
|---|---|---|---|---|---|---|
| Wilcoxon rank-sum test | χ2-test | |||||
| White blood cell count (×109/L)a | 4.38 (3.58–5.53) | 4.31 (3.49–5.27) | 4.90 (3.64–5.73) | 3.50–9.50 | 0.253 | 0.231 |
| Increased | 5 (6.25%) | 2 (3.51%) | 3 (13.04%) | |||
| Decreased | 19 (23.75%) | 15 (26.32%) | 4 (17.39%) | |||
| Neutrophil count (×109/L)a | 2.55 (2.01–3.66) | 2.43 (1.97–3.55) | 2.86 (2.18–3.83) | 1.80–6.30 | 0.401 | 0.714 |
| Increased | 8 (10.00%) | 5 (8.77%) | 3 (13.04%) | |||
| Decreased | 14 (17.50%) | 11 (19.30%) | 3 (13.04%) | |||
| Lymphocyte count (×109/L)a | 1.12 (0.83–1.59) | 1.09 (0.76–1.49) | 1.33 (1.04–1.88) | 1.10–3.20 | 0.019 | 0.148 |
| Increased | – | – | – | |||
| Decreased | 38 (47.50%) | 30 (52.63%) | 8 (34.78%) | |||
| Monocyte count (×109/L)a | 0.41 (0.32–0.53) | 0.41 (0.32–0.52) | 0.41 (0.33–0.53) | 0.10–0.60 | 0.861 | 0.704 |
| Increased | 12 (15.00%) | 8 (14.04%) | 4 (17.39%) | |||
| Decreased | – | – | – | |||
| Platelet count (×109/L)a | 181.5 (148.00–227.50) | 180.00 (148.00–218.00) | 212.00 (148.00–260.00) | 125.0–350.0 | 0.339 | 0.827 |
| Increased | 3 (3.75%) | 2 (3.51%) | 1 (4.35%) | |||
| Decreased | 8 (10.00%) | 5 (8.77%) | 3 (13.04%) | |||
| D-dimer (mg/L)a | 0.40 (0.29–0.58) | 0.40 (0.29–0.57) | 0.40 (0.27–0.59) | <0.22 | 0.864 | – |
| Increased | – | – | – | |||
| Decreased | – | – | – | |||
| Prothrombin time (s)a | 14.00 (12.90–14.00) | 13.30 (12.90–14.00) | 13.70 (13.00–14.00) | 11.5–14.5 | 0.469 | 0.909 |
| Increased | 12 (15.00%) | 8 (14.04%) | 4 (17.39%) | |||
| Decreased | 3 (3.75%) | 2 (3.51%) | 1 (4.35%) | |||
| Activated partial thromboplastin time (s)a | 41.80 (37.20–44.10) | 42.60 (37.70–44.10) | 40.35 (35.50–43.90) | 29.0–42.0 | 0.174 | 0.880 |
| Increased | – | – | – | |||
| Decreased | 13 (26.53%) | 8 (25.81%) | 5 (27.78%) | |||
| Creatinine (μmol/L)a | 63.00 (51.00–84.00) | 73.00 (56.00–84.00) | 54.00 (47.00–86.00) | 45–84 | 0.051 | 0.907 |
| Increased | 19 (23.75%) | 13 (22.81%) | 6 (26.09%) | |||
| Decreased | 6 (7.50%) | 4 (7.02%) | 2 (8.70%) | |||
| Creatine kinase (U/L)a | 78.50 (49.00–151.00) | 77.00 (49.00–155.00) | 81.50 (42.00–122.00) | 18–198 | 0.721 | 0.962 |
| Increased | 8 (10.00%) | 6 (10.53%) | 2 (8.70%) | |||
| Decreased | 30 (37.5%) | 21 (36.84%) | 9 (39.13%) | |||
| Lactate dehydrogenase (U/L)a | 208.00 (185.00–266.00) | 205.00 (183.00–253.00) | 216.00 (190.00–296.00) | 135–214 | 0.376 | 0.587 |
| Increased | 37 (46.25%) | 25 (43.86%) | 12 (52.17%) | |||
| Decreased | 2 (2.50%) | 1 (1.75%) | 1 (4.35%) | |||
| Alanine aminotransferase (U/L)a | 18.00 (12.00–26.00) | 18.50 (12.00–26.00) | 16.00 (12.00–27.00) | ≤33 | 0.821 | 0.505 |
| Increased | 14 (17.50%) | 11 (19.30%) | 3 (13.04%) | |||
| Decreased | – | – | – | |||
| Aspartate aminotransferase (U/L)a | 22.00 (18.00–32.00) | 23.50 (19.50–33.00) | 21.00 (17.00–29.00) | ≤32 | 0.214 | 0.560 |
| Increased | 21 (26.25%) | 16 (28.07%) | 5 (21.74%) | |||
| Decreased | – | – | – | |||
| Bilateral involvement on chest radiographs | 79 (98.75%) | 56 (98.25%) | 23 (100.00%) | 0.522 | ||
a
Mean (SD).